Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

VTVTBullishIndustry Newsnews

High materiality7/10

VTVT completes Phase 3 enrollment for cadisegliatin; topline results expected mid-2027

Oct 5, 2026, 8:14 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Milestone completion signals progress toward topline data and potential approval, which historically can lift biotech names; however, outcome risk remains high until data are disclosed and vetted.

AI summary

What happened, with direct paths to the underlying reporting

vTv Therapeutics announced completion of enrollment in its Phase 3 CATT1 trial of cadisegliatin as an adjunct to insulin for Type 1 diabetes. The 166-patient, six-month study will assess hypoglycemia reduction and glycemic control, with topline results expected mid-2027. Cadisegliatin is a liver-selective glucokinase activator and has FDA Breakthrough Therapy designation.

Completed enrollment in Phase 3 CATT1; 166 patients randomized.
Cadisegliatin is a liver-selective glucokinase activator with FDA Breakthrough designation.
Topline results expected mid-2027; potential to reduce hypoglycemia risk in T1D.
Six-month study; randomized to 800 mg once daily, twice daily, or placebo.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.